PWE-126 Telaprevir With Adjusted dose of Ribavirin in Naive Chc-G1: Efficacy and Treatment in Chc In Hemodialysis Population. Target C (Rct)

@article{Basu2013PWE126TW,
  title={PWE-126 Telaprevir With Adjusted dose of Ribavirin in Naive Chc-G1: Efficacy and Treatment in Chc In Hemodialysis Population. Target C (Rct)},
  author={P. Patrick Basu and Niraj James Shah and Sakina Farhat and Ravi Siriki and K. Mittimanj and M. Rahaman and Srilakshmi Atluri},
  journal={Gut},
  year={2013},
  volume={62},
  pages={A182 - A182}
}
Introduction Chronic hepatitis C (CHC) in Hemodialysis population is 3%. Standard of care (SOC) offers reduced dose of Peg IFN Alfa (p-IFNα) and reduced Ribavirin doses eliciting sub optimal SVR of 27%. Morbidity and mortality of CHC has impact on liver kidney transplant and graft failure. Triple therapy is SOC in CHC. Telaprevir is not cleared renally and hence is safe in dialysis population. This study evaluated the triple therapy in naïve CHC-G1 in hemodialysis in Respond Guided Therapy (RGT… Expand
2 Citations